Universitaetsklinikum Schleswig-Holstein Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Germany (2003)

Organization Overview

First Clinical Trial
2003
NCT00006453
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Chair of the Dept. of Anaesthesiology and Intensive Care Medicine, University of Schleswig-Holstein Campus Kiel | Clinic for Dermatology, Venereology and Allergy, University Clinic Schleswig-Holstein, Campus Kiel | Consultant in Anesthesiology, Dep. of Anesthesiology and Intenisve Care Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Germany | Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Kiel | Martin Schrappe | Neurological pain research and therapy Clinic for Neurology Campus Kiel, University Clinic Schleswig-Holstein, Schittenhelmstr. 10, 24105 Kiel, Germany | Prof. Dr. Stephan Weidinger | Universitaetsklinikum Schleswig-Holstein - Campus Luebeck | University Clinic Schleswig-Holstein | University Hopsital Schleswig Holstein Campus Lübeck | University Hospital of Schleswig-Holstein | University Hospital Schleswig-Holstein | University Hospital Schleswig-Holstein, 24105 Kiel, Germany | University Hospital Schleswig-Holstein, Campus Kiel | University Hospital Schleswig-Holstein, Campus Kiel, Department of Anaesthesiology and Intensive Care Medicine | University hospital Schleswig-Holstein, Germany | University Medical Center, Schleswig-Holstein, Department of Dermatology, Schittenhelmstr. 7, 24105 Kiel, Germany | University of Scghleswig-Holstein, Campus Kiel, Department of Nephrology | University of Schleswig-Holstein | University of Schleswig-Holstein, campus Kiel Department odf Nephrology | University of Schleswig-Holstein, Campus Kiel Department of Nephrolgy | University of Schleswig-Holstein, Campus Kiel Department of Nephrology | University of Schleswig-Holstein, Campus Kiel, Department of Nephrology

Active Ingredients

Drugs in Phase 4 Trials (8)

fluvastatin (lescol) (3 trials)

mycophenolate (CellCept) (2 trials)

oxycodone (oxycontin) (1 trial)

pregabalin (lyrica) (1 trial)

sevoflurane (ultane) (1 trial)

sirolimus (rapamune) (1 trial)

tacrolimus (prograf) (1 trial)

tapentadol (nucynta) (3 trials)

Drugs in Phase 3 Trials (39)

aprepitant (Emend) (1 trial)

asparaginase (elspar) (2 trials)

blinatumomab (blincyto) (2 trials)

bone marrow derived mononuclear cells (1 trial)

bortezomib (velcade) (2 trials)

cannabis (1 trial)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (2 trials)

cobalamin (1 trial)

cyclophosphamide (cytoxan) (5 trials)

cytarabine (cytosar-u) (4 trials)

daunorubicin (cerubidine) (4 trials)

dexamethasone (2 trials)

dimethyl fumarate (tecfidera) (1 trial)

doxorubicin (Doxil) (4 trials)

erwinia asparaginase (Erwinaze) (1 trial)

etoposide (vepesid) (4 trials)

fludarabine (fludara) (3 trials)

gemcitabine (gemzar) (3 trials)

ifosfamide (ifex) (3 trials)

Isatuximab (Sarclisa) (1 trial)

lenalidomide (revlimid) (1 trial)

magnesium (1 trial)

mercaptopurine (purinethol) (4 trials)

methotrexate (1 trial)

naltrexone (revia) (4 trials)

oxygen (1 trial)

paclitaxel (taxol) (3 trials)

pegaspargase (oncaspar) (3 trials)

polyethylene glycol (1 trial)

prednisolone (hydeltra) (2 trials)

prednisone (meticorten) (3 trials)

sodium picosulfate (Preopik) (1 trial)

tioguanine (Lanvis) (4 trials)

topotecan (hycamtin) (1 trial)

urea (3 trials)

vincristine (oncovin) (4 trials)

vindesine (Eldisine) (1 trial)

xenon xe-133 (1 trial)

Drugs in Phase 2 Trials (14)

budesonide (rhinocort) (1 trial)

cetuximab (erbitux) (1 trial)

dacarbazine (dtic-dome) (1 trial)

fluorouracil (efudex) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

ky1005 (1 trial)

mepolizumab (Nucala) (1 trial)

minocycline (minocin) (1 trial)

ofatumumab (arzerra) (1 trial)

pemetrexed (alimta) (1 trial)

sorafenib (nexavar) (1 trial)

tralokinumab (Adtralza) (1 trial)

vatalanib (1 trial)

venetoclax (venclexta) (1 trial)

Drugs in Phase 1 Trials (1)

taiz (2 trials)

Drugs in Other Trials (23)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

alteplase (Activase) (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

autologous umbilical cord blood (1 trial)

busulfan (Myleran) (1 trial)

clonidine (catapres) (1 trial)

cyclosporine (sandimmune) (1 trial)

dobutamine (dobutrex) (1 trial)

infliximab (remicade) (1 trial)

l-cafedrine (1 trial)

leucovorin (1 trial)

lithium (lithonate) (1 trial)

melphalan (alkeran) (1 trial)

midazolam (versed) (1 trial)

mitoxantrone (novantrone) (1 trial)

nicotinamide (1 trial)

poractant alfa (curosurf) (1 trial)

propofol (diprivan) (1 trial)

silicone (1 trial)

sufentanil (1 trial)

theodrenaline (1 trial)

uropidil (1 trial)

vedolizumab (entyvio) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 4)

Cadaver (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Transitional Cell (Phase 3)

Churg-Strauss Syndrome (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Colorectal Neoplasms (Phase 3)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Genital Neoplasms, Female (Phase 3)

Hyperalgesia (Phase 1)

Kidney Neoplasms (Phase 3)

Leukemia (Phase 3)

Leukemia, Large Granular Lymphocytic (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Low Back Pain (Phase 4)

Melanoma (Phase 2)

Neuralgia (Phase 4)

Pancreatic Neoplasms (Phase 3)

Peripheral Nervous System Diseases (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Psoriasis (Phase 3)

Respiratory Aspiration (Phase 3)

Rosacea (Phase 2)

Sarcoma (Phase 2)

Syndrome (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Ulcer (Phase 2)

Ureteral Neoplasms (Phase 3)

Urethral Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial APIs: 85